106 research outputs found
In-line single-mode fiber variable optical attenuator based on electrically addressable microdroplets
We report an in-line, fiber optic, broadband variable optical attenuator employing a side-polished, single-mode optical fiber integrated on a digital microfluidics platform. The system is designed to electrically translate a liquid droplet along the polished surface of an optical fiber using electrowetting forces. This fiber optic device has the advantage of no moving mechanical parts and lends itself to miniaturization. A maximum attenuation of 25 dB has been obtained in the wavelength range between 1520 nm and 1560 nm
Modeling and characterization of an electrowetting based single mode fiber variable optical attenuator
We report an optofluidics-based variable optical attenuator (VOA) employing a tapered side-polished single-mode optical fiber attached to an electrowetting-on-dielectric (EWOD) platform. The side polishing of the fiber cladding gives access to the evanescent field of the guided mode, while the EWOD platform electrically controls the stepwise translation of a liquid droplet along the variable thickness polished cladding of the fiber. The penetration of the evanescent field into the droplet leads to tunneling of optical power from the fiber core to the droplet, from where it is radiatively lost. As a result of the variable cladding thickness, the position of the droplet along the length of the polished fiber determines the degree of penetration of the evanescent field into the droplet. The droplet position can be electrically changed; thus, controlling the optical power loss from the fiber. This approach has been used to demonstrate an optofluidic continuous-fiber VOA typically providing up to 26 dB of broadband attenuation in the 1550-nm transmission window, with a wavelength dependent loss less than 1.1 dB. In this paper, we present the theoretical modeling and experimental characterization of the system, discussing the influence of the design parameters on the performance of this VOA
Real-time assessment of nanoparticle-mediated antigen delivery and cell response
Nanomaterials are increasingly being developed for applications in biotechnology, including the delivery of therapeutic drugs and of vaccine antigens. However, there is a lack of screening systems that can rapidly assess the dynamics of nanoparticle uptake and their consequential effects on cells. Established in vitro approaches are often carried out on a single time point, rely on time-consuming bulk measurements and are based primarily on populations of cell lines. As such, these procedures provide averaged results, do not guarantee precise control over the delivery of nanoparticles to cells and cannot easily generate information about the dynamics of nanoparticle-cell interactions and/or nanoparticle-mediated compound delivery. Combining microfluidics and nanotechnology with imaging techniques, we present a microfluidic platform to monitor nanoparticle uptake and intracellular processing in real-time and at the single-cell level. As proof-of-concept application, the potential of such a system for understanding nanovaccine delivery and processing was investigated and we demonstrate controlled delivery of ovalbumin-conjugated gold nanorods to primary dendritic cells. Using time-lapse microscopy, our approach allowed monitoring of uptake and processing of nanoparticles across a range of concentrations over several hours on hundreds of single-cells. This system represents a novel application of single-cell microfluidics for nanomaterial screening, providing a general platform for studying the dynamics of cell-nanomaterial interactions and representing a cost-saving and time-effective screening tool for many nanomaterial formulations and cell types
An in vitro microfluidic model of microglia migration after stroke
Objectives: Microglia migrate to the site of ischemic insult in response to mediators such as glutamate and ADP being released from damaged or stressed cells and can exert both protective and detrimental effects1. Our present objective is to characterise microglia migration in vitro using a microfluidic model which allows precise chemical concentration gradients to be established over time, mimicking the release of mediators after stroke in vivo. Methods: Microglial cell line, SIM-A9, were seeded in microfluidic culture chambers at 2.5 × 106 cells/ml for 24 hrs prior to exposure to concentration gradients of glutamate (100 µM) or vehicle (DMEM, control), with and without direct LPS (1µg/ml). Real time time-lapse imaging and cell tracking software were used to quantify cell migration velocity, and accumulated and Euclidean distance. Preliminary experiments analysed an average of 24 cell tracks per group (mean ± SD). Results: Microglia were observed to migrate towards increasing chemical concentration gradients compared to control. This directionality effect was supported by an increased average number of cells entering the microchannels and an increased Euclidean distance towards the glutamate gradient versus control (170.36 ± 108.19 µM vs 35.5 ± 36.9 µm, respectively). Interestingly, the addition of direct LPS dampened down the increased Euclidean distance to 75.26 ± 53.5 µm. Compared to vehicle, a concentration gradient of glutamate induced a substantial increase in velocity which was further increased by the additional direct application of LPS (0.33 ± 0.18 µm/min vs 0.58 ± 0.15 µm/min vs 0.65 ± 0.18 µm/min, respectively). A similar pattern was observed for accumulated distance (372.8 ± 203.12 µm vs 651.02 ± 169.4 µm vs 730.4 ± 205.47 µm, respectively). Conclusions: These results suggest that a pro-inflammatory environment limits glutamate-induced directionality and provide novel insight into dynamics of microglia responses after stroke
Microfluidic technologies for immunotherapy studies on solid tumours
Immunotherapy is a powerful and targeted cancer treatment that exploits the body's immune system to attack and eliminate cancerous cells. This form of therapy presents the possibility of long-term control and prevention of recurrence due to the memory capabilities of the immune system. Various immunotherapies are successful in treating haematological malignancies and have dramatically improved outcomes in melanoma. However, tackling other solid tumours is more challenging, mostly because of the immunosuppressive tumour microenvironment (TME). Current in vitro models based on traditional 2D cell monolayers and animal models, such as patient-derived xenografts, have limitations in their ability to mimic the complexity of the human TME. As a result, they have inadequate translational value and can be poorly predictive of clinical outcome. Thus, there is a need for robust in vitro preclinical tools that more faithfully recapitulate human solid tumours to test novel immunotherapies. Microfluidics and lab-on-a-chip technologies offer opportunities, especially when performing mechanistic studies, to understand the role of the TME in immunotherapy, and to expand the experimental throughput when using patient-derived tissue through its miniaturization capabilities. This review first introduces the basic concepts of immunotherapy, presents the current preclinical approaches used in immuno-oncology for solid tumours and then discusses the underlying challenges. We provide a rationale for using microfluidic-based approaches, highlighting the most recent microfluidic technologies and methodologies that have been used for studying cancer–immune cell interactions and testing the efficacy of immunotherapies in solid tumours. Ultimately, we discuss achievements and limitations of the technology, commenting on potential directions for incorporating microfluidic technologies in future immunotherapy studies
Surface enhanced Raman scattering (SERS) based microfluidics for single cell analysis
The integration of surface enhanced Raman scattering (SERS) with droplet microfluidics has the potential to improve our understanding of cellular systems. Herein, we present the first application of SERS droplet microfluidics for single cell analysis. A microfluidic device was used to encapsulate single prostate cancer cells and wheat germ agglutin (WGA) functionalized SERS nanoprobes in water-in-oil droplets that were subsequently locked into a storage droplet array for spectroscopic investigation. The stationary droplets enabled the rapid identification of SERS regions of interest in live cancer cells by allowing collection of “fast” coarse maps over an area of several mm2 followed by “slower” detailed interrogation of the identified hotspots. We demonstrate SERS at cellular resolution via a proof-of-concept assay that detects glycan expression on the surface of prostate cancer cells using WGA modified metallic nanoparticles. The data illustrates the potential of SERS optofluidic systems for high-throughput cell screening and illustrates a previously unobserved high degree of cell-to-cell variability in the size and number of glycan islands
A modular microfluidic platform to enable complex and customisable in vitro models for neuroscience
Disorders of the central nervous system (CNS) represent a global health challenge and an increased understanding of the CNS in both physiological and pathophysiological states is essential to tackle the problem. Modelling CNS conditions is difficult, as traditional in vitro models fail to recapitulate precise microenvironments and animal models of complex disease often have limited translational validity. Microfluidic and organ-on-chip technologies offer an opportunity to develop more physiologically relevant and complex in vitro models of the CNS. They can be developed to allow precise cellular patterning and enhanced experimental capabilities to study neuronal function and dysfunction. To improve ease-of-use of the technology and create new opportunities for novel in vitro studies, we introduce a modular platform consisting of multiple, individual microfluidic units that can be combined in several configurations to create bespoke culture environments. Here, we report proof-of-concept experiments creating complex in vitro models and performing functional analysis of neuronal activity across modular interfaces. This platform technology presents an opportunity to increase our understanding of CNS disease mechanisms and ultimately aid the development of novel therapies
Interdroplet bilayer arrays in millifluidic droplet traps from 3D-printed moulds
In droplet microfluidics, aqueous droplets are typically separated by an oil phase to ensure containment of molecules in individual droplets of nano-to-picoliter volume. An interesting variation of this method involves bringing two phospholipid-coated droplets into contact to form a lipid bilayer in-between the droplets. These interdroplet bilayers, created by manual pipetting of microliter droplets, have proved advantageous for the study of membrane transport phenomena, including ion channel electrophysiology. In this study, we adapted the droplet microfluidics methodology to achieve automated formation of interdroplet lipid bilayer arrays. We developed a ‘millifluidic’ chip for microliter droplet generation and droplet packing, which is cast from a 3D-printed mould. Droplets of 0.7–6.0 μL volume were packed as homogeneous or heterogeneous linear arrays of 2–9 droplets that were stable for at least six hours. The interdroplet bilayers had an area of up to 0.56 mm2, or an equivalent diameter of up to 850 μm, as determined from capacitance measurements. We observed osmotic water transfer over the bilayers as well as sequential bilayer lysis by the pore-forming toxin melittin. These millifluidic interdroplet bilayer arrays combine the ease of electrical and optical access of manually pipetted microdroplets with the automation and reproducibility of microfluidic technologies. Moreover, the 3D-printing based fabrication strategy enables the rapid implementation of alternative channel geometries, e.g. branched arrays, with a design-to-device time of just 24–48 hours
Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT
The alternative splicing of the tau gene, MAPT, generates six protein isoforms in the adult human CNS. Tau splicing is developmentally regulated and dysregulated in disease. Mutations in MAPT that alter tau splicing cause frontotemporal dementia (FTD) with tau pathology, providing evidence for a causal link between altered tau splicing and disease. The use of induced pluripotent stem cell (iPSC) derived neurons has revolutionized the way we model neurological disease in vitro. However, as most tau mutations are located within or around the alternatively spliced exon 10, it is important that iPSC-neurons splice tau appropriately in order to be used as disease models. To address this issue, we analysed the expression, and splicing of tau in iPSC-derived cortical neurons from control patients and FTD patients with the 10+16 intronic mutation in MAPT. We show that control neurons only express the fetal tau isoform (0N3R), even at extended time points of 100 days in vitro. Neurons from FTD patients with the 10+16 mutation in MAPT express both 0N3R and 0N4R tau isoforms, demonstrating that this mutation overrides the developmental regulation of exon 10 inclusion in our in vitro model. Further, at extended time-points of 365 days in vitro, we observe a switch in tau splicing to include six tau isoforms as seen the adult human CNS. Our results demonstrate the importance of neuronal maturity for use in in vitro modeling and provide a system that will be important for understanding the functional consequences of altered tau splicing
- …